JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2006, 55(3):99-109

Cytotoxicity Screening and Mode of Action of Natural and Synthetically Prepared Compounds Usable in Tumour Chemotherapy

S. Letašiová1, S. Jantová1, V. Milata2
1 Fakulta chemickej a potravinárskej technológie Bratislava, Katedra biochémie a mikrobiológie
2 Slovenská technická univerzita Bratislava, Katedra organickej chémie

The paper reviews the current approaches to cytotoxic effect screening and mode of action of natural and synthetic compounds usable in tumour chemotherapy. Oncological diseases belong to the most frequently occurring and the most serious diseases that threaten millions of human lives. A serious complication of anticancer therapy is an inadequate therapeutic answer which is caused by the resistance of the human organism to the employed drugs, chemotherapeutic agents. Therefore the resistance is one of the driving forces which constantly force us to search for new anticancer effective drugs of natural or synthetic origin. Primary screening in vitro, in which by different methods the sensitivity of cancer cells growing in vitro to cytotoxic compounds is monitored, is commonly and routinely used for searching for new potential cytostatics today. The properties of a potential anticancer compound are characterized by different parameters, which include antiproliferative activity, monitoring of structural and functional changes in the cytoplasmic membrane, changes in cell proteins and nucleic acids content, cell metabolism changes, cell cycle changes, induction of apoptosis, enzymatic activity (dihydrofolate reductase, proteinases, proteinkinases, topoisomerases, tymidylatsynthetase), effect on mitochondria, cell cytoskeleton, telomerase activity, etc. By monitoring these parameters, the mode of action of a cytotoxically effective compound can be followed up.

Keywords: cancer cell transformation; cytotoxicity; cell death; cell cycle; cytoskeleton

Received: September 27, 2005; Accepted: March 1, 2006; Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Letašiová S, Jantová S, Milata V. Cytotoxicity Screening and Mode of Action of Natural and Synthetically Prepared Compounds Usable in Tumour Chemotherapy. Čes. slov. farm. 2006;55(3):99-109.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kaušitz, J., Altaner, Č. et al.: In: Onkológia. Bratislava, VEDA, vydavateľstvo Slovenskej akadémie vied, 2003, s. 4-30, 83-85, 138-139.
    2. Altaner, Č.: In: Bunková a molekulárna biológia rakoviny. Bratislava, Liga proti rakovine, 2001, s. 10-21.
    3. Weinberg, R. A.: In: Jediná odrodilá buňka. Jak vzniká rakovina. Praha, ACADEMIA, 1998, s. 48-55.
    4. Ferenčík, M., Škárka B. et al.: In: Biochémia. Bratislava, Slovak Academic Press, 2000, s. 410-411.
    5. http://www.zdravcentra.sk/cps/rde/xchg/zcsk/xsl/3141_1488.html
    6. Klener, P.: In: Protinádorová chemoterapie. Praha, Galén, 1996, s. 80-83, 94, 112, 199-201, 278-279. Go to original source...
    7. Fuery, C. J., Impey, H. L., Roberts, N. J. et al.: Clin. Chem., 2000; 46, s. 620-624. Go to original source...
    8. Kliewer, S. A., Lehman, J., Willson, T.: Science, 1999; 284, s. 757-760. Go to original source... Go to PubMed...
    9. Kolář, Z.: http://www.lmp.upol.cz/download/receptory.ppt
    10. Hulín, I. et al.: In: Patofyziológia. Bratislava, SAP, 2002. s. 108, 214-216.
    11. Kliewer, S. A., Lehmann, J. M., Milburn, M. V. et al.: Recent Prog. Horm. Res., 1999; 54, s. 345-67.
    12. Kliewer, S. A., Xu, H. E., Lambert, M. H., Willson, T. M.: Recent Prog. Horm. Res., 2001; 56, s. 239-263. Go to original source... Go to PubMed...
    13. Bozec, A., Chuzel, F., Chater, S. et al.: J. Endocrinol., 2004; 183, s. 79-90. Go to original source... Go to PubMed...
    14. Alexander, B. T.: Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003; 285, s. R933-R934. Go to original source... Go to PubMed...
    15. Wolfs, T. G., de Vries, B., Walter, S. J. et al.: Am. J. Transplant., 2005; 5, s. 68-75. Go to original source... Go to PubMed...
    16. http://www.clsjep.cz/Ukazclanek2.asp?clanek=14542& jazyk
    17. Salmon, S. E.: Cancer Treat. Rep., 1984; 68 (1), 117-125.
    18. Ferenčík, M., Rovenský, J., Nyulassy, Š.: Imunológia. In: Základné termíny a definície (Druhé prepracované a doplnené vydanie). Bratislava, Slovak Academic Press s.r.o., 2001, s. 26-27.
    19. Barile, F. A.: In: Introduction to in vitro cytotoxicology. Florida, USA, Mechanisms and methods. CRC Press, Boca Raton, 1994, s. 27-45.
    20. Kanďárová, H., Jantová, S., Hojerová, J.: Čes.-slov. Derm., 2004; 79 (2), 75-83.
    21. Roche Molecular Biochemicals. Apoptosis and Cell Proliferation. 2nd revised edition. s. 1-63.
    22. Denizot, F., Lang, R.: J. Immunol. Methods., 1986; 89 (2), 271-277. Go to original source... Go to PubMed...
    23. Jantová, S.: Cytotoxicita, antimikróbna aktivita a mechanizmus účinku prírodných a syntetických látok. Habilitačná práca. CHTF STU, 1999, s. 9-29.
    24. Pisha, E., Chai, H., Lee, I. S. et al.: Nature Med., 1995; 1, 1046-1051. Go to original source... Go to PubMed...
    25. Vopršalová, M., Žáčková, P.: In: Základy toxikologie pro farmaceuty. UK Praha, Nakladetelství Karolinum, 2000, s. 21-27.
    26. Horáková, K., Jantová, S.: Biológia. Bratislava, STU, 1998, s. 170-171.
    27. Barišič, K., Petrik, J., Rumora, L.: Acta Pharm., 2003; 53, 151 - 164.
    28. Babál, P.: Medicínsky monitor, 2003; 1, 1-9.
    29. Romero, D., Gomez-Zapata, M., Luna, A., Garcia-Fernandez A. J.: Toxicol. in Vitro, 2003; 17(3), 293-239. Go to original source... Go to PubMed...
    30. Boudreault, F., Grygorczyk, R.: J. Microsc., 2004; 215(3), 302-312. Go to original source... Go to PubMed...
    31. Zink, D., Andrew, H., Fischer, A. H., Nickerson, J. A.: Cancer, 2004; 4, 677-685. Go to original source... Go to PubMed...
    32. Putnam, K. P., Bombick, D. W., Doolittle, D. J.: Toxicol. in Vitro, 2002; 16(5), 599-607. Go to original source... Go to PubMed...
    33. Albrecht, C. F., Theron, E. J., Kruger, P. B.: S. Afr. Med. J., 1995; 85(9), 853-860. Go to original source...
    34. Veselská, R., Zitterbart, K., Jelínková, Š. et al.: Oncol. Rep., 2003; 10, 1049-1058.
    35. Kanduc, D., Mittelman, A., Serpico, R. et al.: Inter. J. Oncol., 2002; 21, 165-170.
    36. Vermes, I., Haanen, C., Reutelingsperger, C.: J. Immunol. Methods, 200; 243 (1-2), 167-190.
    37. Jantová, S.: In: Chémia a život okolo nás. Bratislava, Vydavateľstvo STU, 2005, s. 108.
    38. An, W. W., Gong, X. F., Wang, M. W. et al.: Acta Pharmacol. Sin., 2004; 25 (11), 1502-1508.
    39. Borisenko, G. G., Matsura, T., Liu, S. X. et al.: 413 (1) 41-52.
    40. Dandrea, T., Hellmold, H., Jonsson, C. et al.: Free Radic Biol. Med., 2004; 36 (7), 881-896. Go to original source... Go to PubMed...
    41. Kim, S. D., Moon, C. K., Eun, S. Y. et al.: Biochem. Biophys. Res. Commun., 2005; 328 (1), 326-334. Go to original source... Go to PubMed...
    42. www.biomedcentral.com/ 1534-5874/2/39/figure/F2
    43. Thornberry, N. A., Lazebnik, Y.: Science, 1998; 281, 1312-1316. Go to original source... Go to PubMed...
    44. Ethell, D. W., Buhler, L. A.: Clin. Immunol., 2003; 23 (6), 439-446. Go to original source... Go to PubMed...
    45. Charlot, J. F., Prétet, J. L., Haughey, C., Mougin, C.: Apoptosis, 2004; 9, 333-343. Go to original source... Go to PubMed...
    46. Costantini, P., Jacotot, E., Decaudin, D., Kroemer, G. J.: Natl. Cancer Inst., 2000; 92, 1042-1053. Go to original source... Go to PubMed...
    47. Cryns, V., Yuan, J.: Genes Dev., 1998; 12, 1551-1570. Go to original source... Go to PubMed...
    48. Hückelhoven, R.: Apoptosis, 2004; 9, 299-307. Go to original source... Go to PubMed...
    49. Holcik, M., Korneluk, R. G.: Nat. Rev. Mol. Cell Biol., 2001; 7, 550-556. Go to original source... Go to PubMed...
    50. Knudson, C. M., Johnson, G. M., Lin, Y., Korsmeyer, S. J.: Cancer Res., 2001; 61, 659-665.
    51. Krueger, A., Baumann, S., Krammer, P. H., Kirchhoff, S.: Mol. Cell Biol., 2001; 21 (24), 8247-8254. Go to original source... Go to PubMed...
    52. Alberts, B., Bray, D., Johnson, A. et al.: In: Základy buněčné biologie. Úvod do molekulární biologie buňky. Ústí nad Labem, Espero Publishing, 1998, s. 547-590.
    53. Nead, M. A., Baglia, L. A., Antinore, M. J. et al.: EMBO J., 1998; 17, 2342-2352.
    54. Juan, G., Darzynkiewicz, Z.: In: Cell Biology (Celis, J. E., ed.) Academic Press, 1998, s. 261-274.
    55. Ojo-Amaize, E. A., Nchekwube, E. J., Cottam, H. B. et al.: Cancer Res., 2002; 62, 4007- 4014.
    56. Gunaratnam, M., Grant, M. H.: Toxicol. in Vitro, 2004; 18 (3), 245-253. Go to original source... Go to PubMed...
    57. http://helios.mol.uj.edu.pl/conf_c/chapters/chap_6.htm
    58. Steinmetz, M. O., Stoffler, D., Müller, S. A. et al.: J. Mol. Biol., 1998; 276, 1-6. Go to original source... Go to PubMed...
    59. Wary, K. K., Maniero, F., Isakoff, S. J. et al.: Cell, 1996; 87 (4), 733-742. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.